Oncternal Therapeutics Inc (FRA:GTU)

€ 5.32 0 (0%) Market Cap: 24.54 Mil Enterprise Value: -103,000.00 PE Ratio: 0 PB Ratio: 0.17 GF Score: 31/100

Q2 2024 Oncternal Therapeutics Inc Earnings Call Transcript
Aug 08, 2024

Earnings
Q4 2023 Oncternal Therapeutics Inc Earnings Call Transcript
Mar 07, 2024

€5.32

Earnings
Q3 2023 Oncternal Therapeutics Inc Earnings Call Transcript
Nov 09, 2023

€4.68 (-9.30%)

Earnings
Q2 2023 Oncternal Therapeutics Inc Earnings Call Transcript
Aug 10, 2023

€5.04 (-10.00%)

Earnings
Oncternal Therapeutics Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Q1 2023 Oncternal Therapeutics Inc Earnings Call Transcript
May 04, 2023

€4.68 (-20.41%)

Earnings
Oncternal Therapeutics Inc To Discuss Strategic Reprioritization and Capital Preservation, Extends Cash Runway into 2025 Transcript
Apr 03, 2023
Q4 2022 Oncternal Therapeutics Inc Earnings Call Transcript
Mar 09, 2023

€15.76 (-0.88%)

Earnings
Q3 2022 Oncternal Therapeutics Inc Earnings Call Transcript
Nov 03, 2022

€19.93 (-2.17%)

Earnings
Q2 2022 Oncternal Therapeutics Inc Earnings Call Transcript
Aug 09, 2022

€22.19 (-0.40%)

Earnings
Q1 2022 Oncternal Therapeutics Inc Earnings Call Transcript
May 05, 2022

€19.83 (-2.90%)

Earnings
Q4 2021 Oncternal Therapeutics Inc Earnings Call Transcript
Mar 10, 2022

€30.42 (+7.49%)

Earnings
Oncternal Therapeutics Inc Host Key Opinion Leader Webinar Transcript
Jan 25, 2022
Oncternal Therapeutics Inc to Announce Agreement with U.S. FDA on Phase 3 Registrational Study Design for Zilovertamab Call Transcript
Jan 04, 2022
Q3 2021 Oncternal Therapeutics Inc Earnings Call Transcript
Nov 04, 2021

€64.56 (+0.88%)

Earnings
Q2 2021 Oncternal Therapeutics Inc Earnings Call Transcript
Aug 05, 2021

€61.52 (-2.47%)

Earnings
Q1 2021 Oncternal Therapeutics Inc Earnings Call Transcript
May 06, 2021

€102.4 (+2.61%)

Earnings
Q4 2020 Oncternal Therapeutics Inc Earnings Call Transcript
Mar 11, 2021

€101 (+15.30%)

Earnings
Q2 2020 Oncternal Therapeutics Inc Earnings Call Transcript
Aug 06, 2020

€47.6 (-5.56%)

Earnings
Oncternal Therapeutics Inc Key Opinion Leader (KOL) Webinar on Cirmtuzumab for Treating Patients with Mantle Cell Transcript
Jul 29, 2020
Q1 2020 Oncternal Therapeutics Inc Earnings Call Transcript
May 07, 2020

€48.8 (+1.67%)

Earnings
Q4 2019 Oncternal Therapeutics Inc Earnings Call Transcript
Mar 16, 2020

€56.8

Earnings
Q3 2019 Oncternal Therapeutics Inc Earnings Call Transcript
Nov 07, 2019

€104 (-3.70%)

Earnings
Q2 2019 Oncternal Therapeutics Inc Earnings Call Transcript
Aug 08, 2019

€76 (+9.83%)

Earnings
GTx, Inc and Oncternal Therapeutics Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company Call Transcript
Mar 07, 2019

Oncternal Therapeutics Inc at Jefferies Healthcare Conference Transcript

Jun 07, 2023 / 08:30PM GMT

Release Date Price: €4.8 (+2.56%)

Transcript

Unidentified Analyst

Good afternoon, everyone. We'll get started now. Welcome to the Jefferies 2023 Global Healthcare Conference. It's my pleasure to introduce James Breitmeyer, the President and CEO of Oncternal Therapeutics. turn it over to you, James.

James Breitmeyer

Oncternal Therapeutics, Inc. - President & CEO

Thank you, and thank you for your time and attention this afternoon. These are our forward-looking statements. Oncternal Therapeutics is a San Diego-based company that is developing products for patients with high unmet medical need, in particular, in hematology and in the area of prostate cancer.

I'm pleased to start my presentation today with the announcement that we opened and treated our first patient yesterday with an autologous ROR1 targeted CAR T therapy called ONCT-808. Right behind that, we have a novel small molecule for the treatment of men with prostate cancer that is resistant to current generation androgen receptor signaling inhibitors. And we also have a ROR1 targeted monoclonal antibody in development that we recently put on

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.